VRTX

Vertex Pharmaceuticals Inc

543.48

USD

+12.72

+2.40%

Nov 04, 11:14 UTC -5

Open

Vertex Pharmaceuticals Inc (VRTX) Earnings

VRTX Earnings Reports

Positive Surprise Ratio

VRTX beat 31 of 43 last estimates.

72%

Next Report

Date of Next Report

Feb 10, 2027

Estimate for Q4 26 (Revenue/ EPS)

$3.59B

$4.77

Implied change from Q3 26 (Revenue/ EPS)

+4.22%

+0.21%

Implied change from Q4 25 (Revenue/ EPS)

+12.41%

-5.17%

Vertex Pharmaceuticals Inc earnings per share and revenue

On Nov 02, 2026, VRTX reported earnings of 4.76 USD per share (EPS) for Q3 26, missing the estimate of 4.88 USD, resulting in a -2.51% surprise. Revenue reached 3.44 billion, compared to an expected 3.49 billion, with a -1.29% difference. The market reacted with a -4.05% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of 4.77 USD, with revenue projected to reach 3.59 billion USD, implying an increase of 0.21% EPS, and increase of 4.22% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Royalty Pharma plc Class A Ordinary Shares

Report Date

Nov 04, 2026 For Q3 26

Estimate

$1.20

Actual

$1.21

Surprise

+0.39%

Amgen Inc

Report Date

Nov 03, 2026 For Q3 26

Estimate

$5.90

Actual

$6.45

Surprise

+9.16%

Alkermes Inc. plc

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.07

Actual

$0.09

Surprise

+225.00%

Viridian Therapeutics, Inc. Common Stock

Report Date

Nov 04, 2026 For Q3 26

Estimate

-$0.98

Actual

-$0.81

Surprise

+18.04%

Harmony Biosciences Holdings, Inc. Common Stock

Report Date

Nov 04, 2026 For Q3 26

Estimate

$1.15

Actual

$0.81

Surprise

-30.03%

uniQure N.V.

Report Date

Nov 04, 2026 For Q3 26

Estimate

-$0.94

Actual

-$0.88

Surprise

+6.39%

UroGen Pharma Ltd. Ordinary Shares

Report Date

Nov 04, 2026 For Q3 26

Estimate

$0.13

Actual

-$0.03

Surprise

-121.79%

Geron Corp

Report Date

Nov 04, 2026 For Q3 26

Estimate

$0.00

Actual

$0.00

Surprise

+100.00%

Nuvectis Pharma, Inc. Common Stock

Report Date

Nov 04, 2026 For Q3 26

Estimate

-$0.24

Actual

-$1.02

Surprise

-313.79%

Oculis Holding AG Ordinary shares

Report Date

Nov 03, 2026 For Q3 26

Estimate

-$0.42

Actual

-$0.30

Surprise

+28.03%

FAQ

What were Vertex Pharmaceuticals Inc's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Vertex Pharmaceuticals Inc reported EPS of $4.76, missing estimates by -2.51%, and revenue of $3.44B, -1.29% below expectations.

How did the market react to Vertex Pharmaceuticals Inc's Q3 2026 earnings?

The stock price moved down -4.05%, changed from $553.15 before the earnings release to $530.76 the day after.

When is Vertex Pharmaceuticals Inc expected to report next?

The next earning report is scheduled for Feb 10, 2027.

What are the forecasts for Vertex Pharmaceuticals Inc's next earnings report?

Based on -- analysts, Vertex Pharmaceuticals Inc is expected to report EPS of $4.77 and revenue of $3.59B for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.